Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1995 Aug;69(8):4972–4978. doi: 10.1128/jvi.69.8.4972-4978.1995

Determinants of attenuation and temperature sensitivity in the type 1 poliovirus Sabin vaccine.

M J Bouchard 1, D H Lam 1, V R Racaniello 1
PMCID: PMC189313  PMID: 7609067

Abstract

To identify determinants of attenuation in the poliovirus type 1 Sabin vaccine strain, a series of recombinant viruses were constructed by using infectious cDNA clones of the virulent type 1 poliovirus P1/Mahoney and the attenuated type 1 vaccine strain P1/Sabin. Intracerebral inoculation of these viruses into transgenic mice which express the human receptor for poliovirus identified regions of the genome that conferred reduced neurovirulence. Exchange of smaller restriction fragments and site-directed mutagenesis were used to identify the nucleotide changes responsible for attenuation. P1/Sabin mutations at nucleotides 935 of VP4, 2438 of VP3, and 2795 and 2879 of VP1 were all shown to be determinants of attenuation. The recombinant viruses and site-directed mutants were also used to identify the nucleotide changes which are involved in the temperature sensitivity of P1/Sabin. Determinants of this phenotype in HeLa cells were mapped to changes at nucleotides 935 of VP4, 2438 of VP3, and 2741 of VP1. The 3Dpol gene of P1/Sabin, which contains three amino acid differences from its parent P1/Mahoney, also contributes to the temperature sensitivity of P1/Sabin; however, mutants containing individual amino acid changes grew as well as P1/Mahoney at elevated temperatures, suggesting that either some combination or all three changes are required for temperature sensitivity. In addition, the 3'-noncoding region of P1/Sabin augments the temperature-sensitive phenotype conferred by 3Dpol. Although nucleotide 2741, 3Dpol, and the 3'-noncoding region of P1/Sabin contribute to the temperature sensitivity of P1/Sabin, they do not contribute to attenuation in transgenic mice expressing the poliovirus receptor, demonstrating that determinants of attenuation and temperature sensitivity can be genetically separated.

Full Text

The Full Text of this article is available as a PDF (252.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Agol V. I., Drozdov S. G., Ivannikova T. A., Kolesnikova M. S., Korolev M. B., Tolskaya E. A. Restricted growth of attenuated poliovirus strains in cultured cells of a human neuroblastoma. J Virol. 1989 Sep;63(9):4034–4038. doi: 10.1128/jvi.63.9.4034-4038.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Cann A. J., Stanway G., Hughes P. J., Minor P. D., Evans D. M., Schild G. C., Almond J. W. Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine. Nucleic Acids Res. 1984 Oct 25;12(20):7787–7792. doi: 10.1093/nar/12.20.7787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Christodoulou C., Colbere-Garapin F., Macadam A., Taffs L. F., Marsden S., Minor P., Horaud F. Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature. J Virol. 1990 Oct;64(10):4922–4929. doi: 10.1128/jvi.64.10.4922-4929.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Colbère-Garapin F., Christodoulou C., Crainic R., Pelletier I. Persistent poliovirus infection of human neuroblastoma cells. Proc Natl Acad Sci U S A. 1989 Oct;86(19):7590–7594. doi: 10.1073/pnas.86.19.7590. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Colston E. M., Racaniello V. R. Poliovirus variants selected on mutant receptor-expressing cells identify capsid residues that expand receptor recognition. J Virol. 1995 Aug;69(8):4823–4829. doi: 10.1128/jvi.69.8.4823-4829.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Colston E., Racaniello V. R. Soluble receptor-resistant poliovirus mutants identify surface and internal capsid residues that control interaction with the cell receptor. EMBO J. 1994 Dec 15;13(24):5855–5862. doi: 10.1002/j.1460-2075.1994.tb06930.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Couderc T., Guédo N., Calvez V., Pelletier I., Hogle J., Colbère-Garapin F., Blondel B. Substitutions in the capsids of poliovirus mutants selected in human neuroblastoma cells confer on the Mahoney type 1 strain a phenotype neurovirulent in mice. J Virol. 1994 Dec;68(12):8386–8391. doi: 10.1128/jvi.68.12.8386-8391.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Couderc T., Martin A., Wychowski C., Girard M., Horaud F., Crainic R. Analysis of neutralization-escape mutants selected from a mouse virulent type 1/type 2 chimeric poliovirus: identification of a type 1 poliovirus with antigenic site 1 deleted. J Gen Virol. 1991 Apr;72(Pt 4):973–977. doi: 10.1099/0022-1317-72-4-973. [DOI] [PubMed] [Google Scholar]
  9. Filman D. J., Syed R., Chow M., Macadam A. J., Minor P. D., Hogle J. M. Structural factors that control conformational transitions and serotype specificity in type 3 poliovirus. EMBO J. 1989 May;8(5):1567–1579. doi: 10.1002/j.1460-2075.1989.tb03541.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Fiszman M., Reynier M., Bucchini D., Girard M. Thermosensitive block of the Sabin strain of poliovirus type I. J Virol. 1972 Dec;10(6):1143–1151. doi: 10.1128/jvi.10.6.1143-1151.1972. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Hogle J. M., Chow M., Filman D. J. Three-dimensional structure of poliovirus at 2.9 A resolution. Science. 1985 Sep 27;229(4720):1358–1365. doi: 10.1126/science.2994218. [DOI] [PubMed] [Google Scholar]
  12. Horie H., Koike S., Kurata T., Sato-Yoshida Y., Ise I., Ota Y., Abe S., Hioki K., Kato H., Taya C. Transgenic mice carrying the human poliovirus receptor: new animal models for study of poliovirus neurovirulence. J Virol. 1994 Feb;68(2):681–688. doi: 10.1128/jvi.68.2.681-688.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Jubelt B., Ropka S. L., Goldfarb S., Waltenbaugh C., Oates R. P. Susceptibility and resistance to poliovirus-induced paralysis of inbred mouse strains. J Virol. 1991 Feb;65(2):1035–1040. doi: 10.1128/jvi.65.2.1035-1040.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kawamura N., Kohara M., Abe S., Komatsu T., Tago K., Arita M., Nomoto A. Determinants in the 5' noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype. J Virol. 1989 Mar;63(3):1302–1309. doi: 10.1128/jvi.63.3.1302-1309.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Koike S., Taya C., Kurata T., Abe S., Ise I., Yonekawa H., Nomoto A. Transgenic mice susceptible to poliovirus. Proc Natl Acad Sci U S A. 1991 Feb 1;88(3):951–955. doi: 10.1073/pnas.88.3.951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. La Monica N., Kupsky W. J., Racaniello V. R. Reduced mouse neurovirulence of poliovirus type 2 Lansing antigenic variants selected with monoclonal antibodies. Virology. 1987 Dec;161(2):429–437. doi: 10.1016/0042-6822(87)90136-X. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. La Monica N., Meriam C., Racaniello V. R. Mapping of sequences required for mouse neurovirulence of poliovirus type 2 Lansing. J Virol. 1986 Feb;57(2):515–525. doi: 10.1128/jvi.57.2.515-525.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Lloyd R. E., Bovee M. Persistent infection of human erythroblastoid cells by poliovirus. Virology. 1993 May;194(1):200–209. doi: 10.1006/viro.1993.1250. [DOI] [PubMed] [Google Scholar]
  19. Macadam A. J., Arnold C., Howlett J., John A., Marsden S., Taffs F., Reeve P., Hamada N., Wareham K., Almond J. Reversion of the attenuated and temperature-sensitive phenotypes of the Sabin type 3 strain of poliovirus in vaccinees. Virology. 1989 Oct;172(2):408–414. doi: 10.1016/0042-6822(89)90183-9. [DOI] [PubMed] [Google Scholar]
  20. Macadam A. J., Ferguson G., Arnold C., Minor P. D. An assembly defect as a result of an attenuating mutation in the capsid proteins of the poliovirus type 3 vaccine strain. J Virol. 1991 Oct;65(10):5225–5231. doi: 10.1128/jvi.65.10.5225-5231.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Macadam A. J., Pollard S. R., Ferguson G., Skuce R., Wood D., Almond J. W., Minor P. D. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology. 1993 Jan;192(1):18–26. doi: 10.1006/viro.1993.1003. [DOI] [PubMed] [Google Scholar]
  22. Martin A., Benichou D., Couderc T., Hogle J. M., Wychowski C., Van der Werf S., Girard M. Use of type 1/type 2 chimeric polioviruses to study determinants of poliovirus type 1 neurovirulence in a mouse model. Virology. 1991 Feb;180(2):648–658. doi: 10.1016/0042-6822(91)90078-p. [DOI] [PubMed] [Google Scholar]
  23. Martin A., Wychowski C., Couderc T., Crainic R., Hogle J., Girard M. Engineering a poliovirus type 2 antigenic site on a type 1 capsid results in a chimaeric virus which is neurovirulent for mice. EMBO J. 1988 Sep;7(9):2839–2847. doi: 10.1002/j.1460-2075.1988.tb03140.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Mendelsohn C. L., Wimmer E., Racaniello V. R. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell. 1989 Mar 10;56(5):855–865. doi: 10.1016/0092-8674(89)90690-9. [DOI] [PubMed] [Google Scholar]
  25. Morrison M. E., He Y. J., Wien M. W., Hogle J. M., Racaniello V. R. Homolog-scanning mutagenesis reveals poliovirus receptor residues important for virus binding and replication. J Virol. 1994 Apr;68(4):2578–2588. doi: 10.1128/jvi.68.4.2578-2588.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Moss E. G., O'Neill R. E., Racaniello V. R. Mapping of attenuating sequences of an avirulent poliovirus type 2 strain. J Virol. 1989 May;63(5):1884–1890. doi: 10.1128/jvi.63.5.1884-1890.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Moss E. G., Racaniello V. R. Host range determinants located on the interior of the poliovirus capsid. EMBO J. 1991 May;10(5):1067–1074. doi: 10.1002/j.1460-2075.1991.tb08046.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Murray M. G., Bradley J., Yang X. F., Wimmer E., Moss E. G., Racaniello V. R. Poliovirus host range is determined by a short amino acid sequence in neutralization antigenic site I. Science. 1988 Jul 8;241(4862):213–215. doi: 10.1126/science.2838906. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Nkowane B. M., Wassilak S. G., Orenstein W. A., Bart K. J., Schonberger L. B., Hinman A. R., Kew O. M. Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984. JAMA. 1987 Mar 13;257(10):1335–1340. [PubMed] [Google Scholar]
  30. Nomoto A., Omata T., Toyoda H., Kuge S., Horie H., Kataoka Y., Genba Y., Nakano Y., Imura N. Complete nucleotide sequence of the attenuated poliovirus Sabin 1 strain genome. Proc Natl Acad Sci U S A. 1982 Oct;79(19):5793–5797. doi: 10.1073/pnas.79.19.5793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Omata T., Kohara M., Kuge S., Komatsu T., Abe S., Semler B. L., Kameda A., Itoh H., Arita M., Wimmer E. Genetic analysis of the attenuation phenotype of poliovirus type 1. J Virol. 1986 May;58(2):348–358. doi: 10.1128/jvi.58.2.348-358.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Pollard S. R., Dunn G., Cammack N., Minor P. D., Almond J. W. Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine. J Virol. 1989 Nov;63(11):4949–4951. doi: 10.1128/jvi.63.11.4949-4951.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Racaniello V. R., Baltimore D. Cloned poliovirus complementary DNA is infectious in mammalian cells. Science. 1981 Nov 20;214(4523):916–919. doi: 10.1126/science.6272391. [DOI] [PubMed] [Google Scholar]
  34. Racaniello V. R., Baltimore D. Molecular cloning of poliovirus cDNA and determination of the complete nucleotide sequence of the viral genome. Proc Natl Acad Sci U S A. 1981 Aug;78(8):4887–4891. doi: 10.1073/pnas.78.8.4887. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Ren R. B., Costantini F., Gorgacz E. J., Lee J. J., Racaniello V. R. Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell. 1990 Oct 19;63(2):353–362. doi: 10.1016/0092-8674(90)90168-e. [DOI] [PubMed] [Google Scholar]
  36. Ren R. B., Moss E. G., Racaniello V. R. Identification of two determinants that attenuate vaccine-related type 2 poliovirus. J Virol. 1991 Mar;65(3):1377–1382. doi: 10.1128/jvi.65.3.1377-1382.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Ren R., Racaniello V. R. Human poliovirus receptor gene expression and poliovirus tissue tropism in transgenic mice. J Virol. 1992 Jan;66(1):296–304. doi: 10.1128/jvi.66.1.296-304.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. SABIN A. B., HENNESSEN W. A., WINSSER J. Studies on variants of poliomyelitis virus. I. Experimental segregation and properties of avirulent variants of three immunologic types. J Exp Med. 1954 Jun 1;99(6):551–576. doi: 10.1084/jem.99.6.551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Tardy-Panit M., Blondel B., Martin A., Tekaia F., Horaud F., Delpeyroux F. A mutation in the RNA polymerase of poliovirus type 1 contributes to attenuation in mice. J Virol. 1993 Aug;67(8):4630–4638. doi: 10.1128/jvi.67.8.4630-4638.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Tatem J. M., Weeks-Levy C., Georgiu A., DiMichele S. J., Gorgacz E. J., Racaniello V. R., Cano F. R., Mento S. J. A mutation present in the amino terminus of Sabin 3 poliovirus VP1 protein is attenuating. J Virol. 1992 May;66(5):3194–3197. doi: 10.1128/jvi.66.5.3194-3197.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. The relation between acute persisting spinal paralysis and poliomyelitis vaccine--results of a ten-year enquiry. WHO Consultative Group. Bull World Health Organ. 1982;60(2):231–242. [PMC free article] [PubMed] [Google Scholar]
  42. Toyoda H., Yang C. F., Takeda N., Nomoto A., Wimmer E. Analysis of RNA synthesis of type 1 poliovirus by using an in vitro molecular genetic approach. J Virol. 1987 Sep;61(9):2816–2822. doi: 10.1128/jvi.61.9.2816-2822.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Westrop G. D., Wareham K. A., Evans D. M., Dunn G., Minor P. D., Magrath D. I., Taffs F., Marsden S., Skinner M. A., Schild G. C. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J Virol. 1989 Mar;63(3):1338–1344. doi: 10.1128/jvi.63.3.1338-1344.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Wimmer E., Hellen C. U., Cao X. Genetics of poliovirus. Annu Rev Genet. 1993;27:353–436. doi: 10.1146/annurev.ge.27.120193.002033. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES